These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 25987446)
21. Biotechnology and new companies arising from academia. Vallance P Lancet; 2001 Nov; 358(9295):1804-6. PubMed ID: 11734259 [TBL] [Abstract][Full Text] [Related]
22. Trends in Modern Drug Discovery. Eder J; Herrling PL Handb Exp Pharmacol; 2016; 232():3-22. PubMed ID: 26330257 [TBL] [Abstract][Full Text] [Related]
23. Stepping up to the plate. Nat Immunol; 2008 Jan; 9(1):1. PubMed ID: 18087245 [No Abstract] [Full Text] [Related]
24. Development of novel IVD assays: a manufacturer's perspective. Metcalfe TA Scand J Clin Lab Invest Suppl; 2010; 242():23-6. PubMed ID: 20515272 [TBL] [Abstract][Full Text] [Related]
25. How to set up collaborations between academia and industrial biotech companies. Pronk JT; Lee SY; Lievense J; Pierce J; Palsson B; Uhlen M; Nielsen J Nat Biotechnol; 2015 Mar; 33(3):237-40. PubMed ID: 25748909 [No Abstract] [Full Text] [Related]
26. Drug industry in "depression". Almog DM Med Sci Monit; 2005 Jan; 11(1):SR1-4. PubMed ID: 15614206 [TBL] [Abstract][Full Text] [Related]
27. Emergence of Chinese drug discovery research: impact of hit and lead identification. Zhou C; Zhou Y; Wang J; Zhu Y; Deng J; Wang MW J Biomol Screen; 2015 Mar; 20(3):318-29. PubMed ID: 25520370 [TBL] [Abstract][Full Text] [Related]
28. HTS and hit finding in academia--from chemical genomics to drug discovery. Frearson JA; Collie IT Drug Discov Today; 2009 Dec; 14(23-24):1150-8. PubMed ID: 19793546 [TBL] [Abstract][Full Text] [Related]
29. [Opportunities for the pharmaceutical industry at the Mexican Genomic Medicine Institute]. Jiménez-Sánchez G Gac Med Mex; 2002; 138(3):291-4. PubMed ID: 12096400 [No Abstract] [Full Text] [Related]
31. [Expectation for the drug development activity in academia]. Inagaki O Yakugaku Zasshi; 2013; 133(2):213-9. PubMed ID: 23370516 [TBL] [Abstract][Full Text] [Related]
32. Who will develop new antibacterial agents? Cole ST Philos Trans R Soc Lond B Biol Sci; 2014; 369(1645):20130430. PubMed ID: 24821916 [TBL] [Abstract][Full Text] [Related]
33. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science. Woosley RL; Myers RT; Goodsaid F Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457 [TBL] [Abstract][Full Text] [Related]
34. Drug discovery and development in the age of molecular medicine. Vallance P; Levick M Clin Pharmacol Ther; 2007 Oct; 82(4):363-6. PubMed ID: 17851574 [TBL] [Abstract][Full Text] [Related]
35. Big data in small places. Maclean D; Kamoun S Nat Biotechnol; 2012 Jan; 30(1):33-4. PubMed ID: 22231089 [No Abstract] [Full Text] [Related]
37. Ask the experts: future of the pharmaceutical industry. Interview by Future Medicinal Chemistry. Cottens S; Eaton M; Fuhr J; Geary S; Johnson DS; Li G; Raveglia L; Robertson GM; Westwell A Future Med Chem; 2011 Nov; 3(15):1863-72. PubMed ID: 22023030 [TBL] [Abstract][Full Text] [Related]
38. Medications development for substance-use disorders: contextual influences (dis)incentivizing pharmaceutical-industry positioning. Janero DR Expert Opin Drug Discov; 2014 Nov; 9(11):1265-79. PubMed ID: 25162124 [TBL] [Abstract][Full Text] [Related]
39. Prescription for an ailing pharmaceutical industry. Demain AL Nat Biotechnol; 2002 Apr; 20(4):331. PubMed ID: 11923826 [No Abstract] [Full Text] [Related]
40. [Strategic construction of an innovative drug development pipeline by industry-academia cooperation - consortium for drug innovation in the Tokai region of Japan]. Akaike A Nihon Yakurigaku Zasshi; 2014 May; 143(5):254-9. PubMed ID: 24813797 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]